PMID- 31567736
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20211204
IS  - 1473-6527 (Electronic)
IS  - 0951-7375 (Linking)
VI  - 32
IP  - 6
DP  - 2019 Dec
TI  - BK polyomavirus-specific antibody and T-cell responses in kidney transplantation: 
      update.
PG  - 575-583
LID - 10.1097/QCO.0000000000000602 [doi]
AB  - PURPOSE OF REVIEW: BK polyomavirus (BKPyV) has emerged as a significant cause of 
      premature graft failure after kidney transplantation. Without effective antiviral 
      drugs, treatment is based on reducing immunosuppression to regain immune control 
      over BKPyV replication. The paradigm of high-level viruria/decoy cells, 
      BKPyV-DNAemia, and proven nephropathy permits early interventions. Here, we 
      review recent findings about BKPyV-specific antibody and T-cell responses and 
      their potential role in risk stratification, immune monitoring, and therapy. 
      RECENT FINDING: Kidney transplant recipients having low or undetectable 
      BKPyV-specific IgG immunoglobulin G (IgG) are higher risk for developing 
      BKPyV-DNAemia if the donor has high BKPyV-specific IgG. This observation has been 
      extended to neutralizing antibodies. Immunosuppression, impaired activation, 
      proliferation, and exhaustion of BKPyV-specific T cells may increase the risk of 
      developing BKPyV-DNAemia and nephropathy. Clearance of BKPyV-DNAemia was 
      correlated with high CD8 T cell responses to human leukocyte antigen (HLA)-types 
      presenting BKPyV-encoded immunodominant 9mers. For clinical translation, these 
      data need to be assessed in appropriately designed clinical studies, as outlined 
      in recent guidelines on BKPyV in kidney transplantation. SUMMARY: Evaluation of 
      BKPyV-specific immune responses in recipient and donor may help to stratify the 
      risk of BKPyV-DNAemia, nephropathy, and graft loss. Future efforts need to 
      evaluate clinical translation, vaccines, and immunotherapy to control BKPyV 
      replication.
FAU - Kaur, Amandeep
AU  - Kaur A
AD  - Department Biomedicine, Transplantation and Clinical Virology, University of 
      Basel.
FAU - Wilhelm, Maud
AU  - Wilhelm M
AD  - Department Biomedicine, Transplantation and Clinical Virology, University of 
      Basel.
FAU - Wilk, Sabrina
AU  - Wilk S
AD  - Department Biomedicine, Transplantation and Clinical Virology, University of 
      Basel.
FAU - Hirsch, Hans H
AU  - Hirsch HH
AD  - Department Biomedicine, Transplantation and Clinical Virology, University of 
      Basel.
AD  - Clinical Virology, Laboratory Medicine.
AD  - Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, 
      Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Infect Dis
JT  - Current opinion in infectious diseases
JID - 8809878
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Antibodies, Viral/*immunology
MH  - Antibody Specificity/immunology
MH  - BK Virus/*immunology
MH  - Host-Pathogen Interactions/*immunology
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunosuppression Therapy/adverse effects
MH  - Infection Control
MH  - Kidney Transplantation/*adverse effects
MH  - Polyomavirus Infections/*diagnosis/*etiology/metabolism/therapy
MH  - T-Lymphocytes/*immunology/metabolism
MH  - Transplant Recipients
EDAT- 2019/10/01 06:00
MHDA- 2020/08/04 06:00
CRDT- 2019/10/01 06:00
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2019/10/01 06:00 [entrez]
AID - 10.1097/QCO.0000000000000602 [doi]
PST - ppublish
SO  - Curr Opin Infect Dis. 2019 Dec;32(6):575-583. doi: 10.1097/QCO.0000000000000602.